Moteur de recherche d’entreprises européennes
Financement de l’UE (5 983 356 €) : Ratification de la CAncère mammaire : comprendre les déterminants du risque et le pronostic des sous-types moléculaires Hor05/05/2015 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Ratification de la CAncère mammaire : comprendre les déterminants du risque et le pronostic des sous-types moléculaires
Breast tumours are heterogeneous, and result from the complex interplay of multiple lifestyle/environmental and genetic risk factors. Through the EU-funded COGS project, we have identified a large number of germline variants that influence the risk of breast cancer. In combination, these variants can identify women at wide ranges of genetic risk, even in the absence of family history of breast cancer. Given that breast cancer is not one disease, it is now essential to better understand how risk factors act together to influence the development of pathologic-molecular subtypes of breast cancer. The aim of B-CAST is to identify women at moderate to high risk of breast cancer, the subtype of cancer that is most likely to develop and the prognosis of that particular subtype. This will be accomplished through large-scale pathologic-molecular analyses of over 20,000 breast tumours, and the integration of these data with unique resources from existing consortia, including germline, lifestyle/environmental, mammographic breast density, pathologic and clinical data. This information will inform the development of risk prediction and prognostication models that will be validated in longitudinal cohorts and clinical studies, and incorporated into online tools. We will also disseminate this knowledge to relevant stakeholders, and evaluate how to translate it into risk-stratified public health and clinical strategies. The current challenge for optimised prevention, early detection, and treatment decisions for breast cancer is understanding the genetic and lifestyle determinants of risk and prognosis of molecular subtypes. B-CAST will add to this understanding and will have immediate application with benefits to women by providing validated risk and prognostication tools. This will empower women and doctors with knowledge to tailor strategies for prevention and treatment. Ultimately, this work should result in reductions in the occurrence, morbidity and mortality of this disease.
| DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG | 268 750 € |
| Foundation for Genomics & Population Health | 228 619 € |
| Fundacio Centre de Regulacio Genomica | 2 308 125 € |
| Fundacio Parc Cientific de Barcelona | 0,00 € |
| HARVARD GLOBAL RESEARCH AND SUPPORT SERVICES Inc. | 0,00 € |
| Institute of Cancer Research: the Royal Cancer Hospital LBG | 383 306 € |
| Karolinska Institutet | 350 000 € |
| Queensland Institute OF Medical Research | 0,00 € |
| STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS | 925 688 € |
| The Chancellor Masters and Scholars of the University of Cambridge | 1 056 119 € |
| Universidad de Santiago de Compostela | 399 000 € |
| Universite Laval | 0,00 € |
| VIB VZW | 63 750 € |
https://cordis.europa.eu/project/id/633784
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
